SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-000409
Filing Date
2021-01-06
Accepted
2021-01-06 16:15:56
Documents
13
Period of Report
2021-01-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vktx-8k_20210104.htm   iXBRL 8-K 46303
  Complete submission text file 0001564590-21-000409.txt   214792

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vktx-20210104.xsd EX-101.SCH 6310
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vktx-20210104_def.xml EX-101.DEF 14536
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vktx-20210104_lab.xml EX-101.LAB 24348
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vktx-20210104_pre.xml EX-101.PRE 15279
6 EXTRACTED XBRL INSTANCE DOCUMENT vktx-8k_20210104_htm.xml XML 5582
Mailing Address 12340 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130
Business Address 12340 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

IRS No.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37355 | Film No.: 21510729
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences